Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PegIntron dose study in metastatic ileal/coecal carcinoid
2006-002275-40Phase 2Terminated
- Sponsor
- Akademiska sjukhuset
- Start
- Dec 2006
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of peginterferon alfa-2b in neuroendocrine carcinoma (NEC) and Carcinoid Tumor (CT) (2 arms), sponsored by Akademiska sjukhuset. Primary endpoints: Tumor response definition and Dose effectiveness objective. Started Dec 2006; status: terminated.
02
Drugs
peginterferon alfa-2b
03
Conditions
neuroendocrine carcinoma (NEC)Carcinoid Tumor (CT)
Beyond the preview
Go deeper on 2006-002275-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002275-40.